CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

Vertex shares have climbed almost 50% over the past year.

3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow ↗

February 27, 2024

Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices ↗

February 26, 2024

Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs.

Via Benzinga

3 Biotech Stocks to Buy and Hold for the Next 10 Years ↗

February 26, 2024

There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon.

CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today ↗

February 23, 2024

Via Benzinga

Smart Money Is Betting Big In CRSP Options ↗

February 22, 2024

Via Benzinga

Check Out What Whales Are Doing With CRSP ↗

February 14, 2024

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today ↗

February 09, 2024

Via Benzinga

Is CRISPR Therapeutics the NVIDIA of gene editing?

February 26, 2024

Buy this stock if you're daring, but avoid it for now if you aren't.

Topics Artificial Intelligence

Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold ↗

February 26, 2024

Watch these five stocks, but the market is slightly extended.

Three S&P 500 Giants Lead This List Of Stocks Near Buy Points ↗

February 24, 2024

The stock market rally pulled back to start the week, but roared higher as booming Nvidia earnings and guidance fueled big AI-led gains. The S&P 500 and Dow Jones hit... Read More

Topics Stocks

Stock Market Rallies To Record High On Nvidia: Weekly Review ↗

February 23, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Topics Stocks

Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday ↗

February 22, 2024

Via Benzinga

Crispr Reports Its First Profit In 10 Quarters, And Shares Fly Out Of A Buy Zone ↗

February 21, 2024

The company recently gained approval in the U.S. and abroad for its first gene-editing drug.

These exciting players could deliver explosive growth over time.

Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought ↗

February 20, 2024

If You Invested $10,000 in CRISPR Therapeutics in 2019, This Is How Much You Would Have Today ↗

February 19, 2024

It would have been a great move.

Looking for high-growth opportunities? Here are three Cathie Wood stocks for long-term investors to consider now.

3 Stocks That Cathie Wood Is Loving Now: February 2024 ↗

February 16, 2024

Crispr Therapeutics shares are trading higher Thursday after Wolfe Research analyst Andy Chen initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares have...

What's Going On With Crispr Therapeutics Stock? ↗

February 15, 2024

Via Benzinga

Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday ↗

February 15, 2024

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday.

Via Benzinga

Topics Stocks

Gene therapy: Why does it cost millions for a single treatment?

February 15, 2024

Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.

The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.

Analysts see over 50% gains in these 2 mid-cap biotech stocks

February 14, 2024

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Topics Artificial Intelligence

CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+ ↗

February 13, 2024

While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential.

3 Gene Editing Stocks With Unprecedented Surge Potential ↗

February 13, 2024

The famous investor owns some huge winners -- and big losers, too.

Cathie Wood Has 37% of Her Ark Invest Portfolio Invested in These 7 Stocks ↗

February 12, 2024

Get the latest investment advice for healthcare stocks in 2024. Discover top picks and growth opportunities for the healthcare sector.

3 Groundbreaking Healthcare Stocks to Buy for Robust Gains ↗

February 11, 2024

These strong buy healthcare stocks are among analysts' favorite picks, and their strong market position tells us why.

3 Strong Buy Healthcare Stocks to Add to Your February Must-Watch List ↗

February 09, 2024

With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.

The 3 Most Undervalued Biotech Stocks to Buy in February 2024 ↗

February 08, 2024

Both companies are proven innovators.

2 Healthcare Stocks to Buy Hand Over Fist in February ↗

February 08, 2024

They aren't all long shots, but they're all innovative.

Cathie Wood Just Bought These 3 Biotech Stocks. Should You? ↗

February 07, 2024

These two Cathie Wood holdings are great long-term buys.

2 Cathie Wood Stocks I Plan on Buying for My Kids' Portfolios ↗

February 05, 2024